

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name Francesco Agustoni

E-mail fragust@libero.it
f.agustoni@smatteo.pv.it
francesco.agustoni@unipv.it

Nationality Italian

WORK EXPERIENCE

- Dates (from – to) 01/11/2008 – 29/06/2009
- *Name and address of employer* National Cancer Institute of Milan, via Venezzan 1, Milan
- Type of business or sector Division of Medical Oncology
- Occupation or position held Medical Doctor
- Main activities and responsibilities Patients health care

- Dates (from – to) 30/06/2009 – 31/12/2009
- *Name and address of employer* National Cancer Institute of Milan, via Venezzan 1, Milan
- Type of business or sector Division of Medical Oncology
- Occupation or position held Fellow, Medical Oncology School (first year, first part)
- Main activities and responsibilities Patients health care, clinical research

- Dates (from – to) 01/01/2010 – 29/06/2010
- *Name and address of employer* Università degli Studi di Milano
Fondazione IRCCS Policlinico Mangiagalli Regina Elena, via F. Sforza 28, Milan
- Type of business or sector U.O. Medicina 1 B
- Occupation or position held Fellow, Medical Oncology School (first year, second part)
- Main activities and responsibilities Patients health care

- Dates (from – to) 30/06/2010 – 29/06/2011
- *Name and address of employer* National Cancer Institute of Milan, via Venezzan 1, Milan
- Type of business or sector Division of Medical Oncology
- Occupation or position held Fellow, Medical Oncology School (second year)
- Main activities and responsibilities Patients health care, clinical research

- Dates (from – to) 30/06/2011 – 29/06/2012
- *Name and address of employer* National Cancer Institute of Milan, via Venezzan 1, Milan
- Type of business or sector Division of Medical Oncology
- Occupation or position held Fellow, Medical Oncology School (third year)
- Main activities and responsibilities Patients health care, clinical research

- Dates (from – to) 30/06/2012 – 29/06/2013
- *Name and address of employer* National Cancer Institute of Milan, via Venezian 1, Milan
- Type of business or sector Division of Medical Oncology
 - Occupation or position held Fellow, Medical Oncology School (fourth year)
- Main activities and responsibilities Patients health care, clinical research

- Dates (from – to) 30/06/2013 – 29/06/2014
- *Name and address of employer* National Cancer Institute of Milan, via Venezian 1, Milan
- Type of business or sector Division of Medical Oncology
 - Occupation or position held Fellow, Medical Oncology School (fifth year)
- Main activities and responsibilities Patients health care, clinical research

- Dates (from – to) 01/08/2014 – 30/11/2016
- *Name and address of employer* National Cancer Institute of Milan, via Venezian 1, Milan
- Type of business or sector Division of Medical Oncology
 - Occupation or position held Medical Oncologist
- Main activities and responsibilities Patients health care, clinical research

- Dates (from – to) 05/12/2016 – 24/11/2017
- *Name and address of employer* University of Colorado, Denver – Anschutz Medical Campus
- Type of business or sector Division of Medical Oncology
 - Occupation or position held Research Fellow
- Main activities and responsibilities Laboratory research in oncogenic-driver biomarkers

- Dates (from – to) 01/03/2018 – 04/01/2019
- *Name and address of employer* ASST Ospedale San Gerardo Monza, via Pergolesi 33, Monza
- Type of business or sector Division of Medical Oncology
 - Occupation or position held Medical Oncologist
- Main activities and responsibilities Patients health care, clinical research

- Dates (from – to) 07/01/2019 – ongoing
- *Name and address of employer* Fondazione IRCCS Policlinico San Matteo, via Golgi 19, Pavia
- Type of business or sector Division of Medical Oncology
 - Occupation or position held Medical Oncologist
- Main activities and responsibilities Patients health care, clinical research

- Dates (from – to) 01/11/2019 – ongoing
- *Name and address of employer* Italian Medical Oncology Association - Lombardia
- Type of business or sector Medical Oncology
 - Occupation or position held Member of board of director
- Main activities and responsibilities Management of the Association, medical oncologists representation

- Dates (from – to) 01/02/2022 – ongoing
- *Name and address of employer* University of Pavia, Strada Nuova 65, Pavia
- Type of business or sector Faculty of Dietistics, Public Health Department, Experimental and Forensic Medicine
 - Occupation or position held Adjunct Professor
- Main activities and responsibilities Teaching of Medical Oncology

- Dates (from – to) 16/10/2022 – ongoing
- *Name and address of employer* University of Pavia, Strada Nuova 65, Pavia
- Type of business or sector Department of Medicine and Medical Therapy
 - Occupation or position held Assistant Professor

- Main activities and responsibilities Teaching of Medical Oncology

EDUCATION AND TRAINING

- Dates (from – to) 1997 - 2002
- Name and type of organisation providing education and training Liceo Scientifico Statale Vittorio Veneto di Milano
- Principal subjects/occupational skills covered High school diploma (scientific area)
 - Title of qualification awarded Diploma
 - Level in national classification (if appropriate) Mark: 94/100
- Dates (from – to) 2002 - 2008
- Name and type of organisation providing education and training Università degli Studi di Milano
- Principal subjects/occupational skills covered Degree in Medicine (in 6 years)
 - Thesis title: Oral fluoropyrimidine-induced “Hand-foot Syndrome” in the treatment of colorectal cancer: clinical and prognostic correlations
 - Title of qualification awarded Medical Doctor
 - Level in national classification (if appropriate) Mark: 106/110
- Dates (from – to) 2009 – 2014
- Name and type of organisation providing education and training Università degli Studi di Milano
- Principal subjects/occupational skills covered Specialization degree in Medical Oncology (in 5 years)
 - Thesis title: Indirect comparisons of harm/benefit profile of EGFR tyrosine kinase inhibitors as first-line treatment in EGFR mutated NSCLC patients: a systematic meta-analysis
 - Title of qualification awarded Medical Oncologist
 - Level in national classification (if appropriate) Mark: 70/70

PERSONAL SKILLS AND COMPETENCES

Acquired in the course of life and career but not necessarily covered by formal certificates and diplomas.

MOTHER TONGUE Italian

OTHER LANGUAGES

- English
- Reading skills GOOD
- Writing skills GOOD
- Verbal skills GOOD

OTHER LANGUAGES

- Reading skills German
- Writing skills BASIC
- Verbal skills BASIC

TECHNICAL SKILLS
AND COMPETENCES
*With computers, specific kinds of
equipment, machinery, etc.*

COMPUTER ABILITIES: OFFICE (WORD, EXCEL, POWER-POINT)

DRIVING LICENSE(S)

Italian driving licenses B, A1
American driving license R (State of Colorado)

ANNEXES**PUBLICATIONS:**

Agustoni F, Platania M. Neoplasia e tubercolosi: quando la PET può trarre in inganno. *Casi clinici in Oncologia* 2009; 31: 16-19.

Procopio G, Verzoni E, **Agustoni F**, et al. Overall survival data with sequential targeted therapies in metastatic renal cell cancer. SIUrO 2011 Abstract and oral communication. *Anticancer Research* 2011 May; 31 (5): 1831.

Platania M, **Agustoni F**, Formisano B, et al. Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. *Target Oncol* 2011 Sep; 6 (3):181-86.

Verzoni E, Buzzoni R, **Agustoni F**, et al. Sequential use of targeted therapies (TT) in metastatic renal cell cancer (mRCC): overall results of a large experience. *European J Cancer* 2011 Sep; 47 (S1): S 520.

Del Vecchio M, Mortarini R, Tragni G, Di Guardo L, Bersani I, Di Tolla G, **Agustoni F**, et al. T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma. *J Clin Oncol* 2011 Nov 10; 29 (32): e783-88.

Celio L, Denaro A, **Agustoni F**, et al. Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. *J Support Oncol* 2012 Mar-Apr; 10 (2): 65-71.

Platania M, **Agustoni F**, Vitali M, et al. Advanced NSCLC patients aged over 80 years: to treat or not to treat? That is the question! AIOM 2011 Abstract. *Tumori* 2011 Oct; 11 (2): S79.

Celio L, Bonizzoni E, **Agustoni F**, et al. Benefit of palonosetron plus single-dose dexamethasone (DEX) on delayed nausea and vomiting due to moderately emetogenic chemotherapy (MEC): a pooled analysis of two phase III trials. AIOM 2011 Abstract and oral communication. *Tumori* 2011 Oct; 11 (2): S106-7.

Di Guardo L, Colonna V, **Agustoni F**, et al. Ipilimumab in previously treated metastatic melanoma: experience of the Istituto Nazionale Tumori of Milan. AIOM 2011 Abstract. *Tumori* 2011 Oct; 11 (2): S148.

Celio L, **Agustoni F**, Testa I, et al. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. *Tumori* 2012 May-Jun; 98 (3): 279-86.

Damian S, Celio L, **Agustoni F**, et al. Is a Dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial. *Oncology* 2013; 84: 371–377.

- Gelsomino F, **Agustoni F**, Niger M, et al. Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small cell lung cancer: the never-ending story. *J Clin Oncol* 2013 Sep 10; 31 (26): 3291-93.
- Haspinger ER, **Agustoni F**, Gelsomino F, et al. Indirect comparison of harm/benefit profile of EGFR-TKIs as first-line treatment in EGFR mutated NSCLC patients: a systematic meta-analysis. AIOM 2013 Abstract. *Tumori* 2013.
- Celio L, **Agustoni F**, Ricchini F, et al. Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two phase III trials. *Future Oncol* 2013 Oct; 9 (10): 1451-58.
- Agustoni F**, Platania M, Vitali M, et al. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. *Cancer Treat Rev* 2014 Feb; 40 (1): 197-203.
- Haspinger ER, Platania M, Bertolini G, Caserini R, Landoni E, Roz E, Garassino MC, Zilembo N, **Agustoni F**, et al. Clinical relevance of CD113 positive cells in locally advanced non-small cell lung cancer. *Ann Oncol* 2014 Sep; Volume 25, Supplement 4, Page 422.
- Berardi R, Caramanti M, Arvat E, Mastroianni C, **Agustoni F**, et al. Syndrome of inappropriate anti-diuretic hormone secretion (SIADH) in cancer patients (Pts): results of the first multicenter italian survey. *Ann Oncol* 2014 Sep; Volume 25, Supplement 4, Page 537.
- Platania M, Valeri B, Marchiano' A, Calareso G, **Agustoni F**, et al. Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer. *Int J Colorctal Dis* 2015 Mar; 30 (3): 429-30.
- Serpico D, Trama A, Haspinger ER, **Agustoni F**, et al. Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. *Ann Oncol* 2015 May; 26 (5): 838-47.
- Haspinger ER, **Agustoni F**, Torri V, et al. Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. *Crit Rev Oncol Hematol* 2015 May; 94 (2): 213-27.
- Celio L, Niger M, Ricchini F, **Agustoni F**, et al. Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy. *Core Evid* 2015 Aug 21; 10: 75-87.
- Signorelli D, Macerelli M, Proto C, Vitali M, Cona MS, **Agustoni F**, et al. Systemic approach to malignant pleural mesothelioma; what news of chemotherapy, targeted agents and immunotherapy. *Tumori* 2016 Jan-Feb; 102 (1): 18-30.

Lo Russo G, Macerelli M, Proto C, Vitali M, Signorelli D, Gallucci R, Platania M, **Agustoni F**, et al. Absence of standard in the management of thymic epithelial tumors. AIOM 2015 Abstract. *Tumori* 2015.

Signorelli D, Cona MS, Lo Russo G, Proto C, Vitali M, Macerelli M, **Agustoni F**, et al. Dysthyroidism during immune checkpoints inhibitors treatment: toxicity or something more? AIOM 2015 Abstract. *Tumori* 2015.

Proto C, Lo Russo G, Macerelli M, Vitali M, **Agustoni F**, et al. LUME trial: searching for survival prognostic factors in malignant pleural mesothelioma. AIOM 2105 Abstract. *Tumori* 2015.

Agustoni F. Tossicità' oculare da chemioterapia e target therapies. Capitolo all'interno di "Manuale di cure di supporto in oncologia". Societa' Editrice Universo, 2015.

Celio L, Bonizzoni E, de Braud F, **Agustoni F**, et al. Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies. *Support Care Cancer* 2016 Mar; 24 (3): 1025-34.

Lo Russo G, Macerelli M, Platania M, Zilembo N, Vitali M, Signorelli D, Proto C, Ganzinelli M, Gallucci R, **Agustoni F**, et al. Small-cell lung cancer: clinical management and unmet needs, new perspectives for an old problem. *Curr Drug Targets* 2017; 18 (3): 341-62.

Agustoni F, Fuca' G, Corrao G, et al. Impact of hyponatremia in a tertiary cancer center: a one-year survey at National Cancer Institute of Milan. ESMO 2016 Abstract. *Ann Oncol* 2016.

Cavaliere S, Galli G, **Agustoni F**, et al. Pro-gastrin releasing peptide (pro-GRP) in small-cell lung cancer staging. AIOM 2016 Abstract. *Tumori* 2016.

Canova S, Cicchiello F, **Agustoni F**, et al. Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: analysis of 318 patients. *Tumori* 2017 Mar 24; 103 (2): 143-47.

Bossi P, Cortinovis D, Fatigoni S, Cossu Rocca M, Fabi A, Seminara P, Ripamonti C, Alfieri S, Granata R, Bergamini C, **Agustoni F**, et al. A randomized, double-blind, placebo-controlled, multicentre study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high dose cisplatin. *Ann Oncol* 2017 Oct 1; 28 (10): 2547-51.

Agustoni F, Hirsch FR. PACIFIC trial: new perspectives for immunotherapy in lung cancer. *Transl Lung Cancer Res* 2018 Feb; 7 (Suppl 1): S19-S24.

Agustoni F, Yu H, Ellison K, et al. Indoleamine 2,3-dioxygenase expression in non-small-cell lung cancer: analyses of prevalence, clinical correlations and prognostic impact

WCLC 2018 Abstract. *J Thorac Oncol* 2018 Oct; Volume 13, Issue 10, Pages S393-4.

Ren S, Rivard CJ, Yu H, Genova C, Rozeboom L, Gao D, Hinz TK, Rikke BA, Wynes MW, Caldwell C, **Agustoni F**, et al. A miRNA panel predicts sensitivity of FGFR Inhibitor in lung cancer cell lines. *Clin Lung Cancer* 2018 Sep; 19 (5): 450-56.

Agustoni F, Suda K, Yu H, et al. EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarker analysis. *Cancer Treat Rev* 2018 Aug 4; 72; 15-27.

Sharma GG, Cortinovis D, **Agustoni F**, et al. A compound L1196M/G1202R ALK mutation in a patient with ALK-positive lung cancer with acquired resistance to Brigatinib also confers primary resistance to Lorlatinib. *J Thorac Oncol* 2019, Nov 14 (11): 257-9.

Luciani A, Marra A, Toschi L, Cortinovis D, Fava S, Filippazzi V, Tuzi A, Cerea G, Rossi S, Perfetti V, Rossi A, Giannetta L, Sala L, Finocchiaro G, Pizzutilo EG, Carelli S, **Agustoni F**, et al. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged \geq 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study. *Clin Lung Cancer* 2020 May. 13: S1525-7304 (20) 30144-3.

Accordino G, Lettieri S, Bortolotto C, Benvenuti S, Gallotti A, Gattoni E, **Agustoni F**, et al. From interconnection between genes and microenvironment to novel immunotherapeutic approaches in upper gastro-intestinal cancer – A multidisciplinary perspective. *Cancers (Basel)* 2020 Jul. 29; 12 (8): 2105.

Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, **Agustoni F**, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT); first results of an international, registry-based, cohort study. *Lancet Oncol* 2020 Jul; 21 (7): 914-22.

Negru ME, Tondini C, Pastorino A, Caccese M, Cariello A, Bertolini A, Buzzatti G, Cinieri S, Comandone A, Grossi F, Franchini M, Caffo O, Garrone O, Mambrini A, Leone F, Chini C, **Agustoni F**, et al. SARS-CoV-2 infection among cancer patients receiving antitumor treatment in Italy: a nationwide observational study (CIPOMO ONCO COVID-19). *Ann Oncol* 2020 Sep; Volume 31, Supplement 4, Pages S1004-5.

Stella GM, Valizia C, Saracino L, **Agustoni F**, et al. Multidisciplinary approach in the evaluation and management of patients with malignant pleural mesothelioma. A single center experience. *Eur Resp J* 2020, 56: 1139.

Bortolotto C, Lancia A, Stelitano C, Montesano M, Merizzoli E, **Agustoni F**, et al. Radiomics features as predictive and prognostic biomarker in NSCLC. *Expert Rev Anticancer Ther* 2021 Mar; 21 (3): 257-66.

Lettieri S, Bortolotto C, **Agustoni F**, et al. The evolving landscape of the molecular epidemiology of malignant pleural mesothelioma. *J Clin Med* 2021 Mar 3; 10 (5): 1034.

Di Cosimo S, Tagliaferri B, Generali D, Giudici F, **Agustoni F**, et al. Baseline Characteristics and outcomes of cancer patients infected with SARS-CoV-2 in the

Lombardy Region, Italy (AIOM-L CORONA): a multicenter, observational, ambispective, cohort study. *Cancers* 2021 Mar 16; 13 (6): 1324.

Aprile G, Basile D, Giaretta R, Schiavo G, La Verde N, Corradi E, Monge T, **Agustoni F**, et al. The clinical value of nutritional care before and during active cancer treatment. *Nutrients* 2021 Apr 5; 13 (4): 1196.

Saracino L, Bortolotto C, Tomaselli S, Fraolini E, Bosio M, Accordino G, **Agustoni F**, et al. Integrating data from multidisciplinary management of malignant pleural mesothelioma: a cohort study. *BMC Cancer* 2021 Jul 1; 21 (1): 762.

Lisini D, Lettieri S, Nava S, Accordino G, Frigerio S, Bortolotto C, Lancia A, Filippi AR, **Agustoni F**, et al. Local therapies and modulation of tumor surrounding stroma in malignant pleural mesothelioma: a translational approach. *Int J Mol Sci* 2021 Aug 20; 22 (16): 9014.

Lasagna A, **Agustoni F**, Percivalle E, et al. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study. *ESMO Open* 2021 Oct, Vol. 6, Issue 5, 1003272.

Agustoni F, Bosco E, Chignoli R, et al. A one-year survey on cancer patients affected by SARS-CoV-2 infection: clinical characteristics and disease evolution in a single Institution experience. AIOM 2021 Abstract. *Tumori* 2021.

Bruni A, Scotti V, Borghetti P, Vagge S, **Agustoni F**, et al. A real-world, multicenter, observational retrospective study of Durvalumab after concomitant or sequential chemoradiation for unresectable stage III non-small cell lung cancer. *Front Oncol* 2021 Nov 16; 11: 802949.

Lasagna A, Secondino S, **Agustoni F**, et al. The resilience of Oncologists during the early time of the COVID-19 pandemic. *Ann Res Oncol* 2021; 1(1): 56-61.

Hirsch FR, Redman MW, Moon J, **Agustoni F**, et al. EGFR high copy number together with high EGFR protein expression predicts improved outcome for Cetuximab-based therapy in squamous cell lung cancer: analysis from SWOG S0819, a phase III trial of chemotherapy with or without Cetuximab in advanced NSCLC. *Clin Lung Cancer* 2022 Jan; 23 (1): 60-71.

Lasagna A, Lilleri D, **Agustoni F**, et al. Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up. *ESMO Open* 2021 Dec 10, Vol. 7, Issue 1, 100359.

Whisenant JB, Baena J, Cortellini A, Huang LC, Lo Russo G, **Agustoni F**, et al. A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERA-VOLT registry. *J Thorac Oncol* 2022 Jan 24; S1556-0864(22)00033-8.

- Cabini RF, Brero F, Lancia A, Stelitano C, Oneta O, Ballante E, Puppo E, Mariani M, Ali E, Bartolomeo V, Montesano M, Merizzoli E, Aluia D, **Agustoni F**, et al. Preliminary report on harmonization of features extraction process using the ComBat tool in the multi-center “Blue Sky Radiomics” study on stage III unresectable NSCLC. *Insights Imaging* 2022 Mar 7; 13 (1): 38.
- Pilotto S, **Agustoni F**, Morelli AM, et al. Nutritional support in lung cancer: time to combine immunonutrition with immunotherapy? *Nutrition* 2022 Mar 3; 98; 111637.
- Catania C, Piperno G, Russo A, Greco C, **Agustoni F**, et al. Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era. *Crit Rev Oncol Hematol* 2022 April 21; 174: 103684.
- Filippi AR, Lancia A, Oneta O, Tsoutzidis N, Bortolotto C, Ali E, Bartolomeo V, La Mattina S, Borghetti P, Stella G, **Agustoni F**, et al. Preliminary results of the “Blue Sky Radiomics” study on stage III NSCLC patients treated with chemo-radiation and consolidation immunotherapy. *Ann Oncol* 2022 Apr; 3: Page S85.
- Agustoni F**, Cortinovis DL, Arcangeli S, et al. Rationale and design of a single-arm, phase 2, multi-center study of chemo-immunotherapy followed by hypo-fractionated radiotherapy and maintenance immunotherapy in patients with unresectable stage III NSCLC: the DEDALUS trial. AIOM 2022 Abstract and Poster. *Tumori* 2022.
- Quaquarini E, Sottotetti F, **Agustoni F**, et al. Clinical and biological variables influencing outcome in patients with advanced non-small cell lung cancer (NSCLC) treated with anti-PD-1/PD-L1 antibodies: a prospective multicenter study. *J Pers Med* 2022 April 24; 12 (5): 679.
- Stella GM, Scialò F, Bortolotto C, **Agustoni F**, et al. Pragmatic expectancy on microbiota and non-small cell lung cancer: a narrative review. *Cancers (Basel)* 2022 Jun 26; 14 (13): 3131.
- Lugini A, Rossi R, Montrone M, Genoca C, **Agustoni F**, et al. Application of liquid biopsy for the detection of genomic biomarkers that can be used for the treatment of patients with stage IV NSCLC: Italian multicenter experience. ISLB 2022 Abstract and Poster.
- Falanga R, Rinaldi P, Primiceri C, Bortolotto C, Oneta O, **Agustoni F**, et al. Feasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience. *Thorac Cancer* 2022 Oct; 13 (19): 2792-98.
- Ciliberto G, Canfora M, Terrenato I, Agnoletto C, **Agustoni F**, et al. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer. *J Exp Clin Cancer Res* 2022 Oct 17; 41 (1): 305.
- Bortolotto C, Stella GM, Messina G, Lo Tito A, Podrecca C, Nicola G, Bellazzi R, Gerbasi A, **Agustoni F**, et al. Correlation between PD-L1 expression of non-small cell lung cancer and data from IVIM-DWI acquired during magnetic resonance of the thorax: preliminary results. *Cancers (Basel)* 2022 Nov 16; 14 (22): 5634.

- Caccialanza R, Cereda E, **Agustoni F**, et al. Multicentre, randomized, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling. *BMC Cancer* 2022 Nov 24; 22 (1): 1212.
- Filippi AR, **Agustoni F**, Arcangeli S, et al. Rationale and design of a single-arm, phase 2, multi-center study of chemo-immunotherapy followed by hypo-fractionated RT and maintenance immunotherapy in patients with unresectable stage III NSCLC: the DEDALUS Trial. *Clin Lung Cancer* 2023 May; 24(3): e122-25.
- Piloni D, Bertuccio FR, Primiceri C, Rinaldi P, Chino V, Abbott DM, Sottotetti F, Bortolotto C, **Agustoni F**, et al. Smoking habit and respiratory function predict patients' outcome after surgery for lung cancer, irrespective of histotype and disease stage *J Clin Med* 2023 Feb 16; 12(4): 1561.
- Cavaliere S, Vitolo V, Barcellini A, Ronchi S, Facoetti A, Campo C, Klersy C, Molinelli S, **Agustoni F**, et al. Immune checkpoint inhibitors and carbon ION radiotherapy in solid cancers with stable disease (ICONIC). *Future Oncol* 2023 Jan 19(3): 193-203.
- Stella GM, Chino V, Putignano P, Bertuccio F, **Agustoni F**, et al. CT scan-guided fine needle aspiration cytology for lung cancer diagnosis through the COVID-19 pandemic: what we have learned. *Tomography* 2023 Mar 31; 9(2): 759-67.
- Bortolotto C, Messina G, Lo Tito A, Stella GM, Pinto A, Podrecca C, Bellazzi R, Gerbasi A, **Agustoni F**, et al. The role of native T1 and T2 mapping times in identifying PD-L1 expression and the histological subtype of NSCLCs. *Cancers (Basel)* 2023 Jun 20; 15(12): 3252.
- Catania C, Filippi AR, Sangalli C, Piperno G, Russano M, Greco C, Scotti V, Proto C, Bennati C, Di Pietro Paolo M, Platania A, Olmetto E, **Agustoni F**, et al. New options and open issues in the management of unresectable stage III and in early-stage NSCLC: a report from an expert panel of Italian medical and radiation oncologists – INTERACTION group. *Crit Rev Oncol Hematol* 2023 Oct; 190: 104108.

Date : 27 October 2023